Abstract
Protein tyrosine phosphatases (PTPs) constitute a large family of enzymes that can exert both positive and negative effects on signaling pathways. They play dominant roles in setting the levels of intracellular phosphorylation downstream of many receptors including receptor tyrosine kinases and G protein-coupled receptors. As observed with kinases, deregulation of PTP activity can also contribute to cancer. This review will examine a broad array of PTP family members that positively affect oncogenesis in human cancer tissues. We will describe the PTP family, their biological significance in oncology, and how recent progress is being made to more effectively target specific PTPs. Finally, we will discuss the therapeutic implications of targeting these oncogenic PTPs in cancer.
Keywords: Cancer, Inhibitors, dual-specificity phosphatases (DSPs), Oncogene, Protein tyrosine phosphatases, Phosphorylation, Tumor suppressor, G protein-coupled receptors (GPCRs), Amplification, Gynecological Cancers
Anti-Cancer Agents in Medicinal Chemistry
Title: Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Volume: 12 Issue: 1
Author(s): Serge Hardy, Sofi G. Julien and Michel L. Tremblay
Affiliation:
Keywords: Cancer, Inhibitors, dual-specificity phosphatases (DSPs), Oncogene, Protein tyrosine phosphatases, Phosphorylation, Tumor suppressor, G protein-coupled receptors (GPCRs), Amplification, Gynecological Cancers
Abstract: Protein tyrosine phosphatases (PTPs) constitute a large family of enzymes that can exert both positive and negative effects on signaling pathways. They play dominant roles in setting the levels of intracellular phosphorylation downstream of many receptors including receptor tyrosine kinases and G protein-coupled receptors. As observed with kinases, deregulation of PTP activity can also contribute to cancer. This review will examine a broad array of PTP family members that positively affect oncogenesis in human cancer tissues. We will describe the PTP family, their biological significance in oncology, and how recent progress is being made to more effectively target specific PTPs. Finally, we will discuss the therapeutic implications of targeting these oncogenic PTPs in cancer.
Export Options
About this article
Cite this article as:
Hardy Serge, G. Julien Sofi and L. Tremblay Michel, Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/187152012798764741
DOI https://dx.doi.org/10.2174/187152012798764741 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Chemokines in the Pathogenesis and as Therapeutical Markers and Targets of HCV Chronic Infection and HCV Extrahepatic Manifestations
Current Drug Targets Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Qigefang Inhibits Migration, Invasion, and Metastasis of ESCC by Inhibiting Gas6/Axl Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews The Synthetic Oleanane Triterpenoid HIMOXOL Induces Autophagy in Breast Cancer Cells via ERK1/2 MAPK Pathway and Beclin-1 Up-regulation
Anti-Cancer Agents in Medicinal Chemistry How to Achieve Near Zero Fluoroscopy During Radiofrequency Ablation of Atrial Fibrillation: A Strategy Used at Two Centers
Current Cardiology Reviews Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets The Role on Endoscopy in Alcohol-Related Diseases
Reviews on Recent Clinical Trials A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry The Effects of the “XGTQ” Medicine in Treating Cirrhosis in Wistar Rats
Current Traditional Medicine Dual Role of S100A8 and S100A9 in Inflammation-Associated Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design